Interesting move in the pharma space - Kyowa Kirin just took back full control of rocatinlimab after ending their collab with Amgen. Amgen's doing a portfolio cleanup, but honestly the timing is wild because the Phase 3 data for this atopic dermatitis treatment just dropped in The Lancet back in November and it looked solid. Hit all the endpoints they needed, showed real skin clearance benefits.

What caught my eye is the long-term extension study data showing durable effects and they're even talking about extended dosing intervals. For a dermatitis candidate, that's a pretty strong position to be in. The OX40 receptor angle seems to be differentiating it from what's already out there.

So now Kyowa Kirin's running the full show on development while Amgen stays on as manufacturer. Makes you wonder if they saw something in the data that makes them want to push harder solo, or if Amgen just needed to trim the portfolio. Either way, this drug's clearly a priority for them - they're confident enough to take it all on. Could be a decent play if they nail the regulatory path.